JP2005538034A - 非ホジキンリンパ腫の治療方法 - Google Patents

非ホジキンリンパ腫の治療方法 Download PDF

Info

Publication number
JP2005538034A
JP2005538034A JP2003550745A JP2003550745A JP2005538034A JP 2005538034 A JP2005538034 A JP 2005538034A JP 2003550745 A JP2003550745 A JP 2003550745A JP 2003550745 A JP2003550745 A JP 2003550745A JP 2005538034 A JP2005538034 A JP 2005538034A
Authority
JP
Japan
Prior art keywords
dose
administered
antibody
week
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003550745A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005538034A5 (https=
Inventor
モーリス ジェイ． ウォリン，
サンドラ ミラン，
デボラ ハースト，
Original Assignee
カイロン コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/293,664 external-priority patent/US20030185796A1/en
Application filed by カイロン コーポレイション filed Critical カイロン コーポレイション
Publication of JP2005538034A publication Critical patent/JP2005538034A/ja
Publication of JP2005538034A5 publication Critical patent/JP2005538034A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2003550745A 2001-12-07 2002-12-06 非ホジキンリンパ腫の治療方法 Withdrawn JP2005538034A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1796801A 2001-12-07 2001-12-07
US10/293,664 US20030185796A1 (en) 2000-03-24 2002-11-12 Methods of therapy for non-hodgkin's lymphoma
PCT/US2002/039253 WO2003049694A2 (en) 2001-12-07 2002-12-06 Methods of therapy for non-hodgkin's lymphoma

Publications (2)

Publication Number Publication Date
JP2005538034A true JP2005538034A (ja) 2005-12-15
JP2005538034A5 JP2005538034A5 (https=) 2006-11-30

Family

ID=26690566

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003550745A Withdrawn JP2005538034A (ja) 2001-12-07 2002-12-06 非ホジキンリンパ腫の治療方法

Country Status (5)

Country Link
EP (1) EP1463524A4 (https=)
JP (1) JP2005538034A (https=)
AU (1) AU2002362098A1 (https=)
CA (1) CA2469045A1 (https=)
WO (1) WO2003049694A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011509953A (ja) * 2008-01-17 2011-03-31 フィロゲン エスピーエー 抗ＥＤｂフィブロネクチン抗体−ＩＬ−２融合タンパク質と、Ｂ細胞、前駆Ｂ細胞および／またはそれらの対応する癌性細胞に結合する分子との組合せ

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3263596A1 (en) 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
PL1631313T3 (pl) 2003-06-05 2015-08-31 Genentech Inc Terapia skojarzona zaburzeń z komórek B
US8147832B2 (en) * 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
MXPA06007236A (es) * 2003-12-22 2006-08-31 Chiron Corp Uso de polimorfismos de receptor fc como diagnosticos para estrategias de tratamiento para trastornos de la respuesta inmune.
BRPI0511187A (pt) 2004-05-20 2007-12-04 Zymogenetics Inc método para tratar cáncer em um indivìduo
TW201422238A (zh) 2004-06-04 2014-06-16 Genentech Inc Ｃｄ２０抗體於治療多發性硬化症之用途及用於該用途之物品
JP2008530232A (ja) * 2005-02-15 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド 化学療法剤、ｉｌ−２および場合により抗ｃｄ２０抗体の組み合わせを使用してリンパ腫を処置する方法
ATE460672T1 (de) 2005-05-20 2010-03-15 Genentech Inc Vorbehandlung einer biologischen probe aus einem individuum mit autoimmunkrankheit
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
WO2007062090A2 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
KR20190140090A (ko) 2007-07-09 2019-12-18 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
EP2200631A1 (en) 2007-10-16 2010-06-30 Zymogenetics, Inc. Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
CN104059955A (zh) 2009-08-11 2014-09-24 弗·哈夫曼-拉罗切有限公司 在无谷氨酰胺的细胞培养基中的蛋白质生产
TW201129384A (en) 2010-02-10 2011-09-01 Immunogen Inc CD20 antibodies and uses thereof
MX391086B (es) 2015-06-24 2025-03-21 Hoffmann La Roche Anticuerpos anti-receptor de transferrina con afinidad diseñada.
NZ741067A (en) 2015-10-02 2023-07-28 Hoffmann La Roche Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
CN115369086B (zh) * 2022-02-22 2023-05-12 北京景达生物科技有限公司 一种nk细胞扩大培养的培养方案

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001247737A1 (en) * 2000-03-24 2001-10-08 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma using a combination of an antibodyto cd20 and interleuking-2

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011509953A (ja) * 2008-01-17 2011-03-31 フィロゲン エスピーエー 抗ＥＤｂフィブロネクチン抗体−ＩＬ−２融合タンパク質と、Ｂ細胞、前駆Ｂ細胞および／またはそれらの対応する癌性細胞に結合する分子との組合せ

Also Published As

Publication number Publication date
AU2002362098A8 (en) 2003-06-23
WO2003049694A3 (en) 2003-11-06
EP1463524A4 (en) 2005-02-09
CA2469045A1 (en) 2003-06-19
AU2002362098A1 (en) 2003-06-23
WO2003049694A2 (en) 2003-06-19
EP1463524A2 (en) 2004-10-06

Similar Documents

Publication Publication Date Title
US20030185796A1 (en) Methods of therapy for non-hodgkin's lymphoma
JP2005538034A (ja) 非ホジキンリンパ腫の治療方法
US20020009427A1 (en) Methods of therapy for non-hodgkin's lymphoma
US7306801B2 (en) Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
AU2018263837B2 (en) Stable formulations of anti-CTLA4 antibodies alone and in combination with programmed death receptor 1 (PD-1) antibodies and methods of use thereof
JP4765039B2 (ja) Ｃｄ４０抗原を発現する癌に対する治療方法。
JP5140164B2 (ja) 抗ＥＤｂフィブロネクチン抗体−ＩＬ−２融合タンパク質と、Ｂ細胞、前駆Ｂ細胞および／またはそれらの対応する癌性細胞に結合する分子との組合せ
CN116134140B (zh) 长效作用的il-15及其用途
KR20210090203A (ko) 또 다른 약리학적 활성제와 조합된 지속 작용성 인터류킨-15 수용체 효현제
JP2007515185A (ja) 免疫応答障害に対する処置ストラテジーのための診断法としてのＦｃレセプター多型の使用
EP2129398A1 (en) Combined human il- 18 and anti cd20 antibody cancer treatment
JP2008530232A (ja) 化学療法剤、ｉｌ−２および場合により抗ｃｄ２０抗体の組み合わせを使用してリンパ腫を処置する方法
KR20210102917A (ko) 종양 질환을 치료하기 위한 il-15 단백질 복합체 연합 pd-l1 항체의 용도
US20030235556A1 (en) Combination IL-2/anti-HER2 antibody therapy for cancers characterized by overexpression of the HER2 receptor protein
US20070274948A1 (en) Methods of Therapy for Chronic Lymphocytic Leukemia
KR20250093156A (ko) Cd80 단백질과 il-2 단백질을 포함하는 융합단백질 및 키메라 항원 수용체를 발현하는 t 세포를 포함하는 암의 예방 또는 치료용 조성물
EP1935431A2 (en) Cancer treatments by using a combination of an antibody against her2 and interleukin-2
NZ768752A (en) Anti-human 4-1 bb antibodies and use thereof
HK1156231A (en) Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061006

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20080904